Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Isofol Medical AB (publ)    ISOFOL   SE0009581051

ISOFOL MEDICAL AB (PUBL)

(ISOFOL)
  Report
End-of-day quote. End-of-day quote NASDAQ OMX STOCKHOLM - 01/22
28.2 SEK   -2.08%
2020ISOFOL MEDICAL : reaches 440 patients in global Phase III AGENT study
AQ
2020DNB MARKETS - ISOFOL MEDICAL : Full steam ahead
AQ
2020DNB MARKETS : Isofol Medical - Licensing deal for Canada
AQ
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Nasdaq Omx Stockholm
01/18/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
29.8 29.1 29.2 28.8 28.2 Last
395311 201445 297982 267661 212686 Volume
-1.97% -2.35% +0.34% -1.37% -2.08% Change
Financials
Sales 2020 19,9 M 2,41 M 2,41 M
Net income 2020 -192 M -23,2 M -23,2 M
Net cash position 2020 104 M 12,5 M 12,5 M
P/E ratio 2020 -10,5x
Yield 2020 -
Sales 2021 18,9 M 2,29 M 2,29 M
Net income 2021 -157 M -18,9 M -18,9 M
Net cash position 2021 128 M 15,4 M 15,4 M
P/E ratio 2021 -15,0x
Yield 2021 -
Capitalization 2 351 M 284 M 284 M
EV / Sales 2020 113x
EV / Sales 2021 117x
Nbr of Employees 12
Free-Float 100%
More Financials
Company
Isofol Medical AB (publ) is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Notations Surperformance© of Isofol Medical AB (publ)
Trading Rating : Investor Rating : -
More Ratings
All news about ISOFOL MEDICAL AB (PUBL)
2020ISOFOL MEDICAL : reaches 440 patients in global Phase III AGENT study
AQ
2020DNB MARKETS - ISOFOL MEDICAL : Full steam ahead
AQ
2020DNB MARKETS : Isofol Medical - Licensing deal for Canada
AQ
2020ISOFOL MEDICAL : Invitation to a conference call and webcast by Isofol in connec..
AQ
2020ISOFOL MEDICAL : announces licensing agreement for Paladin Labs Inc. to commerci..
AQ
2020ISOFOL MEDICAL : Positive Momentum Ahead of AGENT Verdict
AQ
2020ISOFOL MEDICAL : 55 % Overall Response Rate on the safety extension cohorts of t..
AQ
2020ISOFOL MEDICAL : Strengthened patent protection for arfolitixorin in Japan
AQ
2020ISOFOL MEDICAL : DNB Markets - Good momentum in Q2
AQ
2020DNB MARKETS - ISOFOL MEDICAL : Enters into licensing deal for Japan
AQ
2020ISOFOL MEDICAL PUBL : Invitation to a conference call and webcast by Isofol in c..
AQ
2020ISOFOL MEDICAL PUBL : enters licensing agreement with Solasia to develop and com..
AQ
2020ISOFOL MEDICAL PUBL : CEO Ulf Jungnelius has subscribed for all warrants
PR
2020ISOFOL MEDICAL PUBL : CEO Ulf Jungnelius has subscribed for all warrants
AQ
2020ISOFOL MEDICAL PUBL : A milestone is reached with the inclusion of 330 patients ..
AQ
More news
News in other languages on ISOFOL MEDICAL AB (PUBL)

- No features available -

More news
Chart ISOFOL MEDICAL AB (PUBL)
Duration : Period :
Isofol Medical AB (publ) Technical Analysis Chart | ISOFOL | SE0009581051 | MarketScreener
Technical analysis trends ISOFOL MEDICAL AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 38,00 SEK
Last Close Price 28,20 SEK
Spread / Highest target 106%
Spread / Average Target 34,8%
Spread / Lowest Target -25,5%
EPS Revisions
Managers and Directors
NameTitle
Jarl Ulf Birger Jungnelius Chief Executive Officer & Director
Pär-Ola Mannefred Chairman
Gustaf Albért Chief Financial Officer
Karin Ganlöv Senior Medical Director
Roger Tell Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ISOFOL MEDICAL AB (PUBL)0.71%284
MERCK KGAA0.53%74 677
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD11.98%27 883
KYOWA KIRIN CO., LTD.-1.28%14 378
BETTA PHARMACEUTICALS CO., LTD.33.28%8 898
YUHAN CORPORATION-3.60%4 265